Morgan Stanley maintains BioNTech at Overweight, lowers price target to $106 from $114

What happened

Morgan Stanley maintained its Overweight rating on BioNTech but lowered its price target to $106 from $114, a 7.0% decrease. The new target implies 22.0% upside from BioNTech’s Nov. 3 closing price of $86.92.

Confirmed

Global impact / market context

The lower target signals that Morgan Stanley sees less potential value than before, even while keeping its positive rating. If investors give weight to the change, it could affect expectations for BioNTech shares, but the note alone does not establish a change in the company’s business or finances.

Analyst inference

The article lists four recent analyst targets ranging from $110 to $132, all above Morgan Stanley’s new $106 target. This makes its revised estimate lower than the cited peer range, while analyst targets remain opinions rather than promised share prices.

Confirmed

What to watch

1. Compare future analyst updates with Morgan Stanley’s $106 target and the listed $110–$132 range to see whether other firms also lower their expectations. Analyst inference
2. Watch for further changes to Morgan Stanley’s rating or target; the article reports a lower target but gives no explanation for the revision. Confirmed
3. Look for company updates on sales, costs, or research progress that could clarify whether business results support the expectations reflected in analyst targets. Analyst inference

Evidence

• Original source link unavailable